Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,109 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug testing Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimizing PrEP Uptake & Adherence Among Male Sex Workers (MSW) Using a 2-stage Randomization Design

NCT03086057
View directory record Official record
Conditions
Prevention
Interventions
PrEPare for Work: Strength Based Case Management (Stage 1), PrEPare for Work: Adherence Training and Counseling (Stage 2)
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 18, 2026, 12:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

OSA in Pregnant Women With Chronic HTN

NCT03230110
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Pregnancy, Hypertension
Interventions
WP200U home sleep study device
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 18, 2026, 12:25 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

NCT04250545
View directory record Official record
Conditions
Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Sapanisertib, Telaglenastat Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 18, 2026, 12:25 AM EDT
Completed Not applicable Interventional

Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV Medication Adherence

NCT05783297
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment Text (TXTXT), Standard of Care
Behavioral
Lead sponsor
Amy K. Johnson, PhD, MSW
Other
Eligibility
16 Years to 35 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Fort Lauderdale, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 18, 2026, 12:25 AM EDT
Active, not recruiting Phase 1 Interventional

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

NCT01947023
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Dabrafenib Mesylate, Echocardiography Test, Lapatinib, Lapatinib Ditosylate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 18, 2026, 12:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Myocardial Perfusion and Fibrosis in Cancer Survivors

NCT03191461
View directory record Official record
Conditions
Myocardial Fibrosis, Myocardial Injury, Chemotherapeutic Toxicity
Interventions
Adenosine stress test MRI
Diagnostic Test
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 18, 2026, 12:25 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

NCT06577441
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
145
States / cities
Berkeley, California • Irvine, California • Orange, California + 120 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 12:25 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

NCT04875975
View directory record Official record
Conditions
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Interventions
Rozanolixizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 18, 2026, 12:25 AM EDT
Recruiting Phase 3 Interventional

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

NCT05401357
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
9
States / cities
Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 18, 2026, 12:25 AM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 18, 2026, 12:25 AM EDT
Completed Not applicable Interventional

Self-management Adherence in Heart Failure Patients

NCT01964053
View directory record Official record
Conditions
Heart Failure
Interventions
PATCH intervention, Usual care
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
21 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Beatrice, Nebraska • Fairbury, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 18, 2026, 12:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ibuprofen Inhibits Human Sweet Taste

NCT06291337
View directory record Official record
Conditions
Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants, Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy Participants
Interventions
Inhibition of Sweet Taste by Ibuprofen Oral Rinses, Inhibition of Sweet Taste by Naproxen Oral Rinses
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 18, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

NCT05845645
View directory record Official record
Conditions
Healthy Study Participants
Interventions
UCB0599, Esomeprazole, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 18, 2026, 12:25 AM EDT
Terminated Phase 1 Interventional

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

NCT04070781
View directory record Official record
Conditions
Steroid Refractory GVHD, Graft Vs Host Disease
Interventions
Itacitinib, Tocilizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 18, 2026, 12:25 AM EDT
Completed Not applicable Interventional

Technology-enabled Patient Support System for Self-management of CF

NCT03910881
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Open-platform patient support system (PSS) app
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 18, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

NCT07220551
View directory record Official record
Conditions
Healthy Volunteers
Interventions
UCB0022
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 18, 2026, 12:25 AM EDT
Completed Not applicable Interventional Results available

Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding

NCT02442830
View directory record Official record
Conditions
Melena, Gastrointestinal Hemorrhage
Interventions
Early Video Capsule Endoscopy
Device
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 18, 2026, 12:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia

NCT04255745
View directory record Official record
Conditions
Sarcopenia, High Blood Pressure, Hypertension
Interventions
progressive resistance training
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 18, 2026, 12:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long Term Outcomes Follow-up of Glenoid Anchor Peg Component Fixation

NCT02983357
View directory record Official record
Conditions
Arthritis
Interventions
CT, X-Ray, Physical assessment, Questionnaire
Radiation · Other
Lead sponsor
University of Nebraska
Other
Eligibility
44 Years to 94 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 18, 2026, 12:25 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

HPV Vaccine Reduced Dose

NCT06799494
View directory record Official record
Conditions
HPV
Interventions
Gardasil-9, Lidocaine injection, Lorazepam
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 18, 2026, 12:25 AM EDT
Active, not recruiting Not applicable Interventional

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

NCT06068075
View directory record Official record
Conditions
Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma
Interventions
FoundationOne Liquid CDx
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
12 Months to 50 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 18, 2026, 12:25 AM EDT
Not listed Not applicable Interventional

Comparing Strategies for Implementing Primary HPV Screening

NCT04371887
View directory record Official record
Conditions
Cervical Cancer, Human Papillomavirus, Health Knowledge, Attitudes, Practice, Health Care Utilization
Interventions
Local Tailoring
Other
Lead sponsor
Chun Chao
Other
Eligibility
21 Years to 70 Years
Enrollment
45,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 18, 2026, 12:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

NCT02160587
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chloraprep, 0.9% Physiological Saline, ZuraPrep without IPA
Drug · Other
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 18, 2026, 12:25 AM EDT
Terminated Early Phase 1 Interventional

Vitamin D and Cocaine Administration

NCT04826133
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Calcitriol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
30 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 18, 2026, 12:25 AM EDT